Literature DB >> 119643

Radioimmunoassay for type III procollagen peptide and its application to human liver disease.

H Rohde, L Vargas, E Hahn, H Kalbfleisch, M Bruguera, R Timpl.   

Abstract

A sensitive and specific radioimmunoassay was developed for the precursor-specific peptide segment located at the amino end of bovine type III procollagen. Human material showed high cross-reactivity in this assay. Two forms of human procollagen peptides were detected in body fluids. The larger peptide (45K) was found in serum and ascites, and resembled the whole precursor-specific segment which is presumably released from human type III procollagen by a single enzymatic cleavage. The smaller peptide (10K) was found mainly in urine indicating that further degradation of circulating procollagen peptides is required prior to their passage through the kidney. Compared to peptide concentrations in normal human serum two to twenty-fold increases were observed in all patients with alcoholic liver disease, in fifteen of seventeen patients with acute hepatitis, and in ten of fourteen patients with chronic active hepatitis. Much higher levels were detected in ascites fluid. Patients with rheumatoid arthritis and other diseases showed far smaller elevations of the serum peptide. In alcoholic liver disease peptide levels correlated well with inflammation and necrosis observed in liver biopsies, but not with other laboratory parameters.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 119643     DOI: 10.1111/j.1365-2362.1979.tb00912.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  65 in total

1.  Increased procollagen type III peptide in serum of rabbits exposed to diesel engine exhaust.

Authors:  T Suzuki; T Kanoh
Journal:  Bull Environ Contam Toxicol       Date:  1990-05       Impact factor: 2.151

2.  Diagnostic value of measurement of serum type I procollagen carboxy terminal peptides in patients with scirrhous carcinoma of the stomach.

Authors:  K Kohda; N Ito; M Ohwada; K Morita; N Watanabe; Y Kohgo; Y Mogi; Y Niitsu
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

3.  Usefulness of noninvasive transient elastography for assessment of liver fibrosis stage in chronic hepatitis C.

Authors:  Tadashi Takeda; Takahiro Yasuda; Yuji Nakayama; Mika Nakaya; Megumi Kimura; Mariko Yamashita; Ayumi Sawada; Koji Abo; Setsuko Takeda; Hiroki Sakaguchi; Susumu Shiomi; Hitoshi Asai; Shuichi Seki
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

4.  Markers of collagen and basement membrane metabolism in sera of patients with progressive systemic sclerosis.

Authors:  N G Guseva; N V Anikina; R Myllylä; L Risteli; J Risteli; J V Chochlova; K I Kivirikko; V A Nassonova
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

5.  Type I and type III procollagen peptides during hepatic fibrogenesis. An immunohistochemical and ELISA serum study in the CCl4 rat model.

Authors:  B H Davis; J A Madri
Journal:  Am J Pathol       Date:  1987-01       Impact factor: 4.307

Review 6.  Scavenger functions of the liver endothelial cell.

Authors:  B Smedsrød; H Pertoft; S Gustafson; T C Laurent
Journal:  Biochem J       Date:  1990-03-01       Impact factor: 3.857

7.  Noninvasive determination of liver collagen content in chronic hepatitis. Multivariate regression modeling with blood chemical parameters as variables.

Authors:  S Takamatsu; H Nakabayashi; Y Okamoto; H Nakano
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

Review 8.  Connective tissue components of the normal and fibrotic human liver. II. Clinical aspects.

Authors:  G Pott; J Rauterberg; B Voss; U Gerlach
Journal:  Klin Wochenschr       Date:  1982-01-04

9.  CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients.

Authors:  E A Sotaniemi; A Rautio; M Bäckstrom; P Arvela; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

10.  Biochemical and immunological studies of fibroblasts derived from a patient with Ehlers-Danlos syndrome type IV. Demonstrate reduced type III collagen synthesis.

Authors:  M Aumailley; T Krieg; W Dessau; P K Müller; R Timpl; H Bricaud
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.